December 2nd 2023
The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.
November 27th 2023
The combination of lenalidomide and rituximab led to a median progression-free survival of 9 years—with 17 ongoing responses—among patients with mantle cell lymphoma.
November 24th 2023
Manufacturers have announced that they will be withdrawing the new drug application for copanlisib in adult patients with relapsed follicular lymphoma.
November 10th 2023
Lisocabtagene maraleucel is under consideration as a potential treatment option for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
November 4th 2023
The 3-year progression-free survival rate was 94% and the 3-year overall survival rate was 97%.
Oncology Drug Crash Course: Pirtobrutinib (Jaypirca)
Sharon Kauffman, PhD, RN, CNE, NPD-BC, OCN, provides an in-depth look at pirtobrutinib in a downloadable reference sheet.
Odronextamab BLA Is Under Priority Review for 2 Lymphoma Indications
The FDA has granted priority review to odronextamab for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
Interim PET2 Scans May Be Redundant in Frontline Brentuximab Vedotin Regimens Treatments for Hodgkin Lymphoma
Data suggest that frontline treatment brentuximab vedotin elicits superior outcomes in patients with Hodgkin Lymphoma, regardless of PET2 results.
Adding Pembrolizumab to COPDAC-28 Consolidation May Augment Responses in Classical Hodgkin Lymphoma
Patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy may benefit from the addition of pembrolizumab to COPDAC-28 consolidation.
Pembrolizumab Elicits Responses in Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma
Patients with relapsed/refractory primary mediastinal large B-cell lymphoma achieved antitumor responses with pembrolizumab.
Allogeneic CAR T-Cell Therapy CB-010 Demonstrates Potential in Phase 1 Relapsed/Refractory Non-Hodgkin Lymphoma Trial
CB-010 led to a 94% overall response rate among 16 patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Liso-Cel Leads To High Overall Response Rate in Relapsed/Refractory Follicular Lymphoma
Third-line lisocabtagene maraleucel induced a response in 97% of patients with relapsed or refractory follicular lymphoma.
Dose-Dense and Dose-Intense ABVD Is Linked To Improved PFS in Frontline Treatment of Advanced Classical Hodgkin Lymphoma
Intensified doxorubicin, bleomycin, vinblastine, dacarbazine, and granulocyte colony–stimulating factor (ABVD) was associated with a 56% reduction in the relative risk of 3-year progression, relapse, or death.
Pirtobrutinib Elicits Responses in Heavily Pretreated Patients With CLL, SLL
Pirtobrutinib was associated with a 19.6-month median progression-free survival in patients with heavily pretreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
NCCN Guideline Update Outlines Best Practices With High-Dose Methotrexate, Glucarpidase in Patients With ALL/B-Cell Lymphoma
The National Comprehensive Cancer Network has updated their guidelines on high-dose methotrexate and glucarpidase.
Liso-cel Demonstrates Rapid, Durable Responses in Patients with Relapsed/Refractory CLL/SLL
The phase 1/2 TRANSCEND CLL 004 trial met its primary end point by demonstrating that lisocabtagene maraleucel elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Glofitamab Gains Accelerated Approval for Relapsed/Refractory DLBCL
Glofitamab has received accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma.
Mediastinal Radiotherapy May be Safely Omitted Following Frontline Immunochemotherapy in PMBCL
Omitting radiotherapy did not compromise overall survival rates for patients with primary mediastinal B-cell lymphoma.
Second-Line Axi-Cel Bests HDT/HSCT in Prolonging Overall Survival in R/R LBCL
Axicabtagene ciloleucel delivered superior overall survival compared with standard of care in patients with early relapsed or refractory large B-cell lymphoma.
Nivolumab Plus AVD Confers PFS Benefit for Treatment of Advanced-Stage Hodgkin Lymphoma
Patients with advanced-stage Hodgkin lymphoma who received nivolumab plus AVD experienced a 1-year estimated progression-free survival rate of 94% meeting the primary end point of the phase 3 SWOG S1826 trial.
EMR App Increases Patient Referrals to the Leukemia & Lymphoma Society
Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, describes how nurses used an app imbedded in the electronic medical record to refer patients to the Leukemia & Lymphoma Society.
Epcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCL
The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.
Polatuzumab Vedotin Approved in Combination with R-CHP for Treatment-Naïve DLBCL, High-Grade B-Cell Lymphoma
Polatuzumab vedotin has been approved in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma.
Ibrutinib is No Longer Available for Mantle Cell Lymphoma or Marginal Zone Lymphoma in the United States
AbbVie has withdrawn the indications for previously pretreated patients with mantle cell lymphoma and marginal zone lymphoma.
ODAC Votes in Favor Of Polatuzumab Vedotin in Patients With Treatment Naïve LBCL
The FDA’s Oncologic Drugs Advisory Committee voted 11 to 2 in support of the benefit-risk profile displayed by polatuzumab vedotin-piiq in patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified.
Smith Discusses Importance of Adherence When Integrating Pirtobrutinib Into Clinical Practice
Leslie Smith, DNP, RN, APRN-CNS, BMTCN, AOCNS, highlights the pirtobrutinib approval for mantle cell lymphoma, and what she anticipates will encompass best nursing practices with the newly approved agent.
Hematologic Oncology Undergoes Transformation With Drug Updates and Approvals
Kathryn Maples, PharmD, BCOP, highlights recent approvals, and updated labeling, along with drug removals, across leukemia, lymphoma, and multiple myeloma.
Magrolimab Plus Rituximab/Chemo Delivers Responses in Relapsed/Refractory DLBCL
At 11.3 months of follow-up, magrolimab, rituximab, gemcitabine, and oxaliplatin yielded an overall response rate of 51.5%, including a complete response rate of 39.4%, among patients with relapsed or refractory diffuse large B-cell lymphoma.
FDA Approves Zanubrutinib for CLL/SLL
The FDA has approved zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The prescribing label comes with warnings for hemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrythmias.
Frontline Zanubrutinib/Rituximab, Short-Course R-DHAOx Elicits Preliminary Results in Mantle Cell Lymphoma
Among 17 patients with mantle cell lymphoma, the complete remission rate with first-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin was 88.2%.
Induction and Maintenance With Ibrutinib Proves Effective for Mantle Cell Lymphoma
Adding induction to standard chemoimmunotherapy followed by autologous stem cell transplantation and maintenance ibrutinib was highly effective in patients with mantle cell lymphoma.
Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL
Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.
Frontline Pola-R-CHP, CAR-T Second-Line Therapy Are Not Cost-Effective Choices For Patients With DLBCL
An economic analysis showed that neither polatuzumab vedotin nor CD19-directed CAR T-cell therapy are likely to be the most cost-effective for patients with diffuse large B-cell lymphoma based on their high costs and current long-term survival estimates.
Glofitamab Induces Promising Complete Response Rate in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, elicited encouraging response rates in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 1/2 study.
Mosunetuzumab Shows High Response Rates in Relapsed/Refractory Follicular Lymphoma
Mosunetuzumab, an off-the-shelf outpatient therapy with a fixed duration of treatment, demonstrated promising responses in patients with relapsed/refractory follicular lymphoma.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512